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Abstract: Several, if not all adrenergic β-blockers (β-Bs), accumulate progressively inside 
secretory vesicles in a time- and concentration-dependent manner, and could be considered 
to be false neurotransmitters. This transmitter effect is most likely unrelated to their ability 
to block adrenergic receptors, but it could explain the delay in lowering arterial pressure in 
hypertensive patients. We have developed a new drug to monitor the accumulation of β-Bs 
inside living cells, RCTM-3, which fluoresces in the visible spectrum. Here we describe 
the procedure to synthesize this new compound, as well as its fluorescent properties, 
pharmacological profile and its accumulation inside the secretory vesicles of PC12 cells. 
Keywords: exocytosis; false neurotransmitter; secretory vesicle; TIRF 
 
1. Introduction 
The use of radiolabeled molecules has demonstrated that adrenergic β-blockers (β-Bs) are 
accumulated and secreted by chromaffin cells [1,2]. Moreover, we recently demonstrated that β-Bs 
could exert their delayed effects as antihypertensive agents through a mechanism that is not directly 
related to their capacity as blockers of β-receptors but rather, to their progressive accumulation in 
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secretory vesicles of sympathetic cells [3]. Other classical drugs like amphetamines [4], tyramine [5] 
or hydralazine [6] can also be taken up by secretory vesicles, thereby displacing the natural 
neurotransmitter. Such substances sharing this characteristic are usually termed as false 
neurotransmitters. Indeed, when the material accumulated possesses a specific activity, as occurs with 
β-Bs, co-secretion causes the pharmacological antagonism of catecholamines at the synaptic junction. 
Although most of the commercially available β-Bs fluoresce, their excitatory spectra are in the 
ultraviolet range, which means they are of little use for studies of subcellular localization. For instance, 
we can detect the release of labetalol, the most fluorescent commercially available β-B (excitation 
λ335/emission λ420 nm), yet its accumulation inside cells cannot be monitored at these wavelengths 
as they promote autofluorescence of the cell when observed by epi-fluorescence microscopy [3]. In 
addition to classical tools like acridine orange [7] or quinacrine [8], new fluorescent false 
neurotransmitters have been used to monitor the accumulation of amines in secretory vesicles [9]. 
Thus, to demonstrate that β-Bs are effectively accumulated into secretory vesicles, molecules that 
fluoresce strongly in the visible spectrum while maintaining their β-blocking activity are required.  
Here, we describe the synthesis of several β-Bs based on modifications to propranolol, the 
prototypic β-B, as well as the characterization of their fluorescent properties, and of their α- and 
β−adrenergic blocking activity. 
2. Results and Discussion 
We used propranolol, a prototypic β-B, as the template for our molecular design. As the side chain of 
antagonists is similar or identical to that of the isoprenaline agonist, the initial intention was to simply 
modify propranolol by adding an extra aromatic ring and forming an anthracene (compound RCTM-1, 
Table 1). RCTM-1 fluoresced strongly and had moderate blocking activity. However, the drug was very 
unstable and was rapidly hydrolyzed. Thus, we developed other compounds with a view to stabilizing the 
molecule by adding an extra aromatic ring (RCTM-2 and -6), by linking the side chain to the central 
aromatic rings (RCTM-3, -4, -5 and -7) and/or by modifying the substituent of the rings (RTCM-3 and -7). 
When these compounds were analyzed, the increase in the size and rigidity of the aromatic side 
provoked a loss in the blocking capacity and on occasion, in fluorescent yield (Table 1). Only RTCM-3 
(Pat. P200801297) possessed sufficient blocking potency (IC50 14 µM) and fluorescent excitation in the 
visible range (Table 1). As other well known β-Bs possess α-blocking activity (labetalol, carvedilol), we 
also assessed the effects of the RCTM’s on α-adrenergic receptors in rat aorta rings pre-contracted with 
noradrenaline. As expected, none of the compounds tested affected the vascular contractile response 
triggered by noradrenaline (Table 1). Accordingly, we centered our studies on RTCM-3. 
After overexpression of neuropeptide Y (NPY) coupled to the enhanced green fluorescent protein 
(NPY-EGFP) we could observe a pattern typical of a vesicular distribution (Figure 2B). Neuropeptide 
Y is a well-documented vesicular peptide that is selectively packaged into secretory organelles [10,11], 
and the sorting of this protein to large dense core vesicles is only observed in newly synthesized 
vesicles as old granules do not fluorescence. When PC12 cells were incubated for 10 min with RCTM-3 
(10 µM), a similar typical vesicular pattern was also observed (Figure 2A). When both images from 
the same cell were merged, 67 ± 1.3% of RTCM-3 labeling co-localized with NPY-EGFP  
(286 vesicles from 8 cells, Figure 2C), and 86.2 ± 1.3% of the RTCM-3 pixels were co-localized with 
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those of NPY-EGFP. The LDCV that contained NPY-EGFP but not RCTM-3 fluorescence probably 
corresponded to immature vesicles that had not been acidified, while the RCTM-3 labeled vesicles 
with no NPY are likely to be old vesicles formed prior to NPY-EGFP transfection. When adrenal 
chromaffin cells were used instead of PC12, the vesicles labeled with RCTM-3 were larger than the 
protein labeled vesicles, indicating that a higher proportion of ‘old’ vesicles is present as opposed to 
newly synthesized ones (not shown). 
Table 1. Chemical structures, EC50 in rat atria and aorta, as well as the fluorimetric 
properties of the new compounds. 
Compound MW Chemical structure IC50 (rat atria)
(µM) 
IC50 (rat aorta) 
(µM) 
Fluorescent 
profile λ (nm) 
RCTM-1 309.40 0.6 >30 365/435 
RCTM-2 347.45 >30 >30 356/394 
RCTM-3 340.41 14.1 >30 425/480 
RCTM-4 309.40 0.2 >30 350/376 
RCTM-5 323.42 18.2 >30 346/420 
RCTM-6 333.42 >30 >30 344/770 
RCTM-7 310.39 >30 >30 390/425 
RCTM-8 493.61 >30 n.d. 315/550 
RCTM-9 309.40 O N
HOH
>30 n.d. 334/426 
RCTM-10 297.39 O N
HOH






>30 n.d. 317/346 
n.d. Activity not determined. Fluorescent profile in terms of max excitation/max emission wavelengths (in nm) 
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When the fluorescent spectrum of RCTM-3 was studied (Figure 1), three peaks were evident in the 
excitation spectra and one in the emission spectra, characteristics that made it ideal to use in living 
cells that do not autofluorescence when excited at 425 nm. We also explored the pH dependence of 
this fluorescence as secretory vesicles have a pH of about 5.5 [8]. However, we only observed 
important changes in the excitation spectra of RCTM-3 at very acid pHs (e.g., pH 4.2), which is 
unlikely to be reached within vesicles (Figure 1). Nevertheless, the strong fluorescence of this 
compound means that even the spectral position of our laser line can be used (460 nm, blue square in 
Figure 1A). Despite these unfavorable conditions, the accumulation of RCTM-3 can be monitored by 
TIRF microscopy.  
Figure 1. Fluorescent spectra of RCTM-3. (A). Excitation spectra showing three peaks at 
240, 320 and 425 nm. The blue rectangle identifies the portion of the spectra illuminated 
by the laser used for TIRF microscopy; (B). Emission spectra, the green rectangle indicates 
the portion of the spectra selected by the band-pass filter used for TIRF microscopy. The 
colored lines indicate the fluorescent spectra obtained at different pH’s. 
 
Figure 2. Intracellular location of RTCM-3 in a PC12 cell. (A). TIRFM images obtained 
from eight PC12 cells incubated for 10 min with RTCM-3 (10 µM); and (B). transfected 
with human pro-NPY tagged with EGFP (NPY-EGFP) Panel (C) shows a merged image of 
the other two images where coincident pixels are yellow (Bar, 10 µm). 
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β-blocker activity has classically been assayed in isolated rat atria. Although this preparation beats 
spontaneously at ≈200 b.p.m., β-adrenergic agonists like adrenaline can increase the beating frequency 
to about 300 b.p.m. We demonstrated that adrenaline (300 nM) can maintain this frequency of beating 
for at least 20 min, sufficient time to test eight cumulative concentrations of β-Bs (10−8–3 × 10−5 M: 
Figure 3). When compared with the β1 cardioselective blocker atenolol, RCTM-3 showed moderate 
blocking activity (IC50 14.1 vs. 0.28 µM) but no action on rat aorta rings pre-contracted with 
phenylephrine (Table 1). This response is typical of β-Bs that lack α activity, usually the initial test in 
screening procedures. 
Figure 3. Inhibitory effects of RCTM-3 on isolated rat atria. Once stabilized, the preparations 
were stimulated with adrenaline (300 nM) and the frequency of beating was measured and 
normalized to 100%. Cumulative concentrations of no drug (control), RCTM-3 or atenolol 
were added to the organ bath. Data show the means ± SEM from 8–10 different experiments. 
 
To reveal the presence of β-Bs within subcellular structures such as PC12 secretory vesicles, we 
performed experiments using total internal reflection fluorescence microscopy (TIRFM). PC12 cells 
were transfected with a NPY-EGFP plasmid and 48 h later they were incubated with RCTM-3 (10 µM) 
for 10 min. Double labeled structures were typically seen, suggesting the co-localization of EGFP 
(green) and RCTM-3 (blue: Figure 3).  
Over twenty years ago the unexpected accumulation and secretion of radiolabeled β-Bs in 
chromaffin cells was demonstrated, as well as the increase of radioactivity in the bathing media when 
secretion is stimulated [1]. Recently, we also showed that the accumulation of β-Bs like atenolol, 
labetalol and propranolol (false neurotransmitters) has a significant effect on the quantum release of 
adrenaline [3]. Likewise, we demonstrated that the β-B labetalol was co-liberated with catecholamines. 
However, at that time we could not demonstrate the selective accumulation of β-Bs inside secretory 
vesicles as the fluorescence of the available β-Bs was largely affected by cell autofluorescence. The 
availability of RCTM-3 now provides direct evidence that these organelles do indeed accumulate β-Bs. 
Thus, the use of these fluorescent derivatives opens new perspectives for studying the interaction of 
drugs that affect secretory organelles at the subcellular level. 





1H-NMR spectra were recorded at 400 or 300 MHz, whereas 13C-NMR spectra were recorded at  
75 or 100 MHz. The chemical shifts are reported relative to internal Me4Si and the coupling constants 
are given in Hz. Chromatography was performed on 60 Å and 0.2–0.5 mm silica gel columns and the 
compounds were visualized by use of UV light, 2.5% phosphomolybdic acid in ethanol, or vanillin 
with acetic and sulfuric acid in ethanol with heating. All solvents were purified by standard techniques. 
Reactions requiring anhydrous conditions were performed under nitrogen and anhydrous magnesium 
sulfate was used to dry the solutions. 
1-(Anthracen-1-yloxy)-3-(isopropylamino)propan-2-ol (RCTM-1, Scheme 1). NaH (124 mg, 3.1 mmol, 
60% oil dispersion) was added to a solution of anthracen-1-ol (0.5 g, 2.6 mmol) in dry tetrahydrofuran 
THF (26 mL) at room temperature. The mixture was stirred for 10 min and epibromohydrine (0.33 mL, 
3.9 mmol) and tetrabutylammonium iodide (0.1 g, 0.26 mmol) were then added. The reaction was 
stirred overnight, after which TLC showed that the starting material had disappeared. The reaction 
mixture was then diluted with Et2O, and the mixture was washed with an aqueous saturated NH4Cl 
solution, dried, filtered, concentrated and purified by silica gel flash-chromatography, yielding the 
glycidyl ether (456 mg, 70% yield) as an oil. The glycidyl ether (0.4 g, 1.6 mmol) was mixed with 
isopropylamine (0.34 mL, 4.0 mmol) in EtOH (2 mL/mmol), refluxed for 3 h and left stirring at room 
temperature overnight. The solvent was evaporated and the crude mixture was purified by silica gel 
flash-chromatography, to yield RCTM-1 (470 mg, 95s% yield) as a light brown solid: m.p. 127–129 ºC; 
1H-NMR (CDCl3, 300 MHz) δ 1.34 (m, 6H), 3.19 (m, 3H), 4.12 (dd, J = 4.9, 9.8 Hz, 1H), 4.20 (dd,  
J = 4.9, 9.8 Hz, 1H), 4.65 (m, 1H), 5.56 (br s, 2H), 6.55 (d, J = 7.5 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 
7.43 (m, 2H), 7.54 (d, J = 8.4 Hz, 1H), 7.93 (d, J = 7.2 Hz, 1H), 8.08 (d, J = 8.7 Hz, 1H), 8.31 (s, 1H), 
8.86 (s, 1H); 13C-NMR (CDCl3, 75 MHz) δ 20.4 (q), 20.5 (q), 48.6 (t), 50.3 (d), 66.8 (d), 69.8 (t), 102.4 (d), 
120.7 (d), 124.5 (s), 124.9 (d), 125.0 (d), 125.5 (d), 127.6 (d), 128.6 (d), 131.0 (s), 131.7 (s), 132.3 (s), 
153.8 (s); HRMS (ESI): m/z: calculated for C20H24NO2 [M+ + H]: 310.1807, found: 310.1808. 
Scheme 1. Preparation of RCTM-1. 
 
1-(Isopropylamino)-3-(pyren-1-ylmethoxy)propan-2-ol (RCTM-2, Scheme 2). The same procedure as 
that used above to obtain RCTM-1 was applied to 1-pyrenemethanol on a 200 mg (0.86 mmol) scale, 
yielding the amino alcohol RCTM-2 (260 mg, 87% yield in two steps) as a pale yellow solid: m.p. 
79−84 ºC; 1H-NMR (CDCl3, 300 MHz) δ 1.02 (m, 6H), 2.63 (dd, J = 8.1, 11.9 Hz, 1H), 2.75 (m, 2H), 3.23 
(br s, 2H), 3.59 (m, 2H), 3.95 (m, 1H), 5.23 (s, 2H), 7.99 (m, 4H), 8.14 (m, 4H), 8.34 (d, J = 9.2 Hz, 1H); 
13C-NMR (CDCl3, 75 MHz) δ 22.0 (q), 22.1 (q), 48.9 (d), 49.0 (t), 68.4 (d), 71.8 (t), 72.5 (t), 123.1 (d), 
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124.2 (d), 124.5 (s), 124.7 (s), 125.0 (d), 125.7 (d), 126.9 (d), 127.1 (d), 127.3 (d), 127.6 (d), 129.2 (s), 
130.5 (s), 130.8 (s), 131.0 (s), 131.2 (s); HRMS (ESI): m/z: calculated for C23H26NO2 [M+ + H]: 
348.1964, found: 348.1959. 
Scheme 2. Preparation of RCTM-2. 
 
10-(2-Hydroxy-3-(isopropylamino)propyl)-4-methoxyacridin-9(10H)-one (RCTM-3, Scheme 3). The 
same procedure as that used above to obtain RCTM-1 was applied to 9-hydroxy-4-methoxyacridine on 
a 200 mg (0.89 mmol) scale, yielding the amino alcohol RCTM-3 (190 mg, 63% yield in two steps) as 
a yellow solid: m.p. 178−182 ºC; 1H-NMR (CDCl3, 400 MHz) δ 0.92 (m, 6H), 2.34 (dd, J = 9.0, 11.7 Hz, 
1H), 2.53 (dd, J = 2.8, 11.8 Hz, 1H), 2.67 (m, 1H), 3.80 (s, 3H), 4.05 (br s, 3H), 4.48 (m, 2H), 6.96 (m, 
3H), 7.42 (dd, J = 7.2, 7.2 Hz, 1H), 7.81 (m, 2H), 8.14 (d, J = 7.9 Hz, 1H); 13C-NMR (CDCl3, 100 MHz) 
δ 22.0 (q), 22.0 (q), 49.0 (d), 49.8 (t), 55.1 (t), 56.3 (q), 69.1 (d), 115.4 (d), 117.9 (d), 119.2 (d), 121.4 (d), 
121.9 (d), 122.5 (s), 125.2 (s), 126.5 (d), 133.3 (d), 134.6 (s), 145.1 (s), 149.5 (s), 178.1 (s);  
IR (CHCl3) (cm−l) 3327, 3045, 2970, 1631, 1602, 1493, 1362, 1249; HRMS (ESI): m/z: calculated for 
C20H25N2O3 [M+ + H]: 341.1865, found: 341.1867. 
Scheme 3. Preparation of RCTM-3. 
 
1-(Isopropylamino)-3-(phenanthren-9-yloxy)propan-2-ol (RCTM-4, Scheme 4). The same procedure 
as that used above to obtain RCTM-1 was applied to 9-phenanthrol on a 200 mg (1.03 mmol) scale, 
yielding the amino alcohol RCTM-4 (203 mg, 64 % yield in two steps). The synthesis, and the 
spectroscopic and physical data for this compound have been described previously [12]. 
Scheme 4. Preparation of RCTM-4. 
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1-(Anthracen-9-ylmethoxy)-3-(isopropylamino)propan-2-ol (RCTM-5, Scheme 5). The same 
procedure as that used above to obtain RCTM-1 was applied to 9-anthracenemethanol on a 200 mg 
(0.96 mmol) scale, yielding the amino alcohol RCTM-5 (203 mg, 64% yield in two steps) as a light 
brown solid: m.p. 82−84 ºC; 1H-NMR (CDCl3, 400 MHz) δ 0.98 (m, 6H), 2.53 (dd, J = 8.1, 11.8 Hz, 1H), 
2.53 (dd, J = 3.7, 12.1Hz, 1H), 2.69 (m, 1H), 3.23 (br s, 2H), 3.62 (m, 2H), 3.87 (m, 1H), 5.46 (d,  
J = 11.6 Hz, 1H), 5.49 (d, J = 11.6 Hz, 1H), 7.47 (dd, J = 7.8, 7.8 Hz, 2H), 7.55 (dd, J = 6.9, 6.9 Hz, 
2H), 7.99 (d, J = 8.4 Hz, 2H), 8.37 (d, J = 8.8 Hz, 2H), 8.43 (s, 1H); 13C-NMR (CDCl3, 100 MHz)  
δ 22.5 (q), 48.9 (d), 49.4 (t), 65.3 (t), 68.8 (d), 72.9 (t), 124.3 (d), 125.0 (d), 126.3 (d), 128.4 (d), 128.6 (s), 
129.0 (d), 131.0 (d), 131.4 (s); HRMS (ESI): m/z: calculated for C21H26NO2 [M+ + H]: 324.1964, 
found: 324.1963. 
Scheme 5. Preparation of RCTM-5. 
 
1-(Isopropylamino)-3-(pyren-1-yloxy)propan-2-ol (RCTM-6, Scheme 6). The same procedure as that 
used above to obtain RCTM-1 was applied to 1-hydroxypyrene on a 45 mg (0.21 mmol) scale, 
although the first reaction was carried out at 50 ºC, yielding the amino alcohol RCTM-6 (64 mg, 91% 
yield in two steps) as a light yellow solid: m.p. 168−172 ºC; 1H-NMR (CDCl3, 400 MHz) δ 1.49 (m, 6H), 
3.38 (m, 2H), 3.55 (m, 1H), 4.15 (dd, J = 5.5, 9.6 Hz, 1H), 4.22 (dd, J = 4.5, 9.6 Hz, 1H), 4.95 (m, 1H), 
7.02 (d, J = 8.5 Hz, 1H), 7.59 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 9.0 Hz, 1H), 7.74 (d, J = 9.0 Hz, 1H), 7.85 
(m, 3H), 7.97 (d, J = 7.5 Hz, 1H), 8.32 (d, J = 9.1 Hz, 1H); 13C-NMR (CDCl3, 100 MHz) δ 19.0 (q), 
19.2 (q), 48.0 (t), 51.8 (d), 66.0 (d), 70.2 (t), 108.9 (d), 119.9 (s), 120.8 (d), 124.2 (d), 124.3 (d), 124.6 (s), 
125.1 (d), 125.3 (d), 125.5 (s), 126.0 (d), 126.6 (d), 127.0 (d), 131.4 (d), 131.5 (d), 151.7 (s); HRMS 
(ESI): m/z: calculated for C22H24NO2 [M+ + H]: 334.1807, found: 334.1800. 
Scheme 6. Preparation of RCTM-6. 
 
10-(2-Hydroxy-3-(isopropylamino)propyl)acridin-9(10H)-one (RCTM-7, Scheme 7). The same 
procedure as that used above to obtain RCTM-1 was applied to acridone on a 100 mg (0.51 mmol) 
scale, yielding the amino alcohol RCTM-7 (58 mg, 64% yield in two steps) as yellow solid: m.p. 
99−101 ºC; 1H-NMR (CD3OD, 400 MHz) δ 1.21 (t, J = 6.2 Hz, 6H), 3.00 (dd, J = 9.0, 12.3 Hz, 1H), 3.09 
(m, 2H), 4.38 (m, 1H), 4.51 (dd, J = 3.6, 16.0 Hz, 1H), 4.65 (dd, J = 8.8, 16.0 Hz, 1H), 7.24 (dd,  
J = 7.5, 7.5 Hz, 2H), 7.74 (m, 2H), 7.86 (m, 2H), 8.33 (dd, J = 1.7, 8.0 Hz, 2H); 13C-NMR (CD3OD, 
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100 MHz) δ 21.3 (q), 21.4 (q), 50.4 (t), 50.8 (t), 51.1 (d), 68.6 (d), 117.8 (d), 122.9 (d), 123.2 (s), 128.1 (d), 
135.4 (d), 144.1 (s), 179.9 (s); IR (CHCl3) (cm−l) 3688, 3432, 3020, 1604, 1493; HRMS (ESI): m/z: 
calculated for C19H23N2O2 [M+ + H]: 311.1760, found: 311.1764. 
Scheme 7. Preparation of RCTM-7. 
 
Dansyl analogue of propanolol (RCTM-8, Scheme 8). The synthesis for this compound was described 
previously by Atlas and Levitzki [13]. 
Scheme 8. Preparation of RCTM-8. 
 
1-(Anthracen-9-yloxy)-3-(isopropylamino)propan-2-ol (RCTM-9, Scheme 9). The same procedure as 
that used above to obtain RCTM-1 was applied to anthrone on a 200 mg (1.03 mmol) scale, yielding 
the amino alcohol RCTM-9 (143 mg, 45% yield in two steps). The synthesis, and the spectroscopic 
and physical data for this compound have been described elsewhere [12].  
Scheme 9. Preparation of RCTM-9. 
 
1-(9H-Fluoren-9-yloxy)-3-(isopropylamino)propan-2-ol (RCTM-10, Scheme 10). The same procedure 
as that used above to obtain RCTM-1 was applied to 9-hydroxyfluorene on a 200 mg (1.10 mmol) 
scale, yielding the amino alcohol RCTM-10 (228 mg, 70% yield in two steps) as a light yellow solid: 
m.p. 83−84 ºC; 1H-NMR (CDCl3, 400 MHz) δ 1.05 (m, 6H), 2.56 (m, 1H), 2.68 (m, 1H), 2.79 (m, 1H), 
3.13 (m, 4H), 3.80 (m, 1 H), 5.65 (s, 1H), 7.29 (dd, J = 7.5, 7.5 Hz, 2H), 7.37 (dd, J = 7.2, 7.2 Hz, 2H), 
7.58 (d, J = 7.2 Hz, 2H), 7.64 (d, J = 7.2 Hz, 2H); 13C-NMR (CDCl3, 100 MHz) δ 23.0 (q), 49.4 (d),  
49.8 (t), 67.6 (t), 69.3 (d), 81.2 (d), 120.4 (d), 125.9 (d), 128.0 (d), 128.0 (d), 129.5 (d), 141.3 (s), 142.9 (s); 
Anal. calculated for C19H23NO2 C 76.73, H 7.80, N 4.71, found: C 76.55, H 7.78, N 4.69.  
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Scheme 10. Preparation of RCTM-10. 
 
1-((5H-Dibenzo[a,d][7]annulen-5-yl)oxy)-3-(isopropylamino)propan-2-ol (RCTM-11, Scheme 11). The 
same procedure as that used above to obtain RCTM-1 was applied to dibenzosuberenol on a 500 mg 
(2.40 mmol) scale, yielding the amino alcohol RCTM-11 (414 mg, 53% yield in two steps) as a white 
solid: m.p. 112−114 ºC; 1H-NMR (DMSO-d6, 500 MHz, 363 K) δ 0.98 (d, J = 6.4 Hz, 6H), 2.53 (m, 
1H), 2.66 (m, 1H), 2.72 (m, 1H), 2.98 (br s, 2H), 3.41 (s, 2H), 3.72 (s, 1H), 5.01 (br s, 1H), 7.12 (s, 2H), 
7.29 (dd, J = 7.0, 7.0 Hz, 2H), 7.41 (m, 4H), 7.65 (m, 2H); 13C-NMR (DMSO-d6, 125 MHz, 363 K)  
δ 23.2 (q), 23.3 (q), 48.6 (d), 50.6 (t), 69.6 (d), 72.8 (t), 79.6 (d), 126.9 (d), 128.6 (d), 128.6 (d), 133.4 (s), 
139.3 (s); Anal. calculated for C21H25NO2 C 77.98, H 7.79, N 4.33, found: C 78.14, H 7.64, N 4.28. 
Scheme 11. Preparation of RCTM-11. 
 
3.2. Fluorescence 
Fluorescent spectra were obtained on a Cary Eclipse spectrofluorimeter (Varian Cary Eclipse, 
Agilent Technologies, Santa Clara, CA, USA) after dissolving the molecules in DMSO and then 
diluting them in saline buffer at the pH indicated. 
3.3. Isolated Rat Atria and Aorta Rings 
All animal procedures were performed in agreement with institutional and national guidelines and 
regulations and approved by the Ethical Committee of the University of La Laguna (res#49/2004). The 
organ baths were prepared as described elsewhere [14]. Briefly, animals were sacrificed by 
decapitation, their hearts were rapidly removed and the right atrium was placed in a 4 mL organ bath 
cup. A basal tension of 1 g was applied and the contractions monitored using an isometric transducer at 
a temperature of 37 ºC in Krebs-bicarbonate solution (in mM: NaCl [119], KCl [4.7], MgSO4 [1.2], 
KH2PO4 [1.2], CaCl2 [2.5], NaHCO3 [25] and glucose [13]) continuously bubbled with 95% O2, 5% 
CO2 mixture to maintain the pH at 7.4. 
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Thoracic aortas were excised and cleaned of surrounding fat and connective tissues. Slices of ≈2 mm 
were cut carefully to avoid endothelial damage, and they were mounted in the organ bath as described 
above using Krebs-bicarbonate solution and applying a basal tension of 1 g. The data were sampled at 
400 Hz using Chart for Macintosh and Powerlab (ADInstruments, Dunedin, New Zealand), and the 
data was quantified and analyzed using Graphpad Prism 5 software (La Jolla, CA, USA). 
3.4. Neuropeptide Y Construct 
The human pro-neuropeptide Y construct fused to EGFP (NPY-EGFP) was kindly provided by  
W. Almers (Vollum Institute, Oregon Health & Science University) [10,11]. 
3.5. PC12 Cell Culture and Transfection 
PC12 cells were maintained in 75-mL flasks at 37 °C and 5% CO2 using RPMI 1640 supplemented 
with 10% fetal calf serum and 5% horse serum. For TIRFM experiments, PC12 cells in suspension 
were nucleofected using a Nucleofector device and following the manufacturer’s protocol. Briefly,  
1 × 106 cells were dissociated and re-suspended in 100 µL of the specific Amaxa kit solution (Amaxa 
GmbH, Koeln, Germany) containing NPY-EGFP (2 µg) cDNA, and they were transferred to an 
electroporation cuvette. Cells were electroporated using the U29 cell specific program and they were 
then plated at an approximate density of 2.5 × 106 cells on poly-L-lysine-coated 18 mm diameter 
coverslips (n = 1.518; Warner Instruments, Hamdem, CT), which were placed in 6-well plates. The cells 
were incubated for 5 h in RPMI without sera and antibiotics, after which the medium was supplemented 
with 10% FBS and the cells were allowed to adhere overnight. The cells were used 48 h later. 
3.6. Fluorescence Microscopy 
Cells were visualized on an inverted microscope (Zeiss 200M, Carl Zeiss, Jena, Germany) using a 
1.45 NA objective (alpha Fluar, 100X/1.45, Zeiss). The objective was coupled to the coverslip using 
an immersion fluid (n488 = 1.518; Zeiss). For evanescent field illumination, the expanded beam of an 
argon ion laser (Lasos, Lasertechnik GmbH, Germany) was band-pass filtered and used to selectively 
excite different fluorophores. Different filters were used for each fluorophor analyzed and the beam 
was focused off-axis position at the rear focal plane of the objective. When passing through the 
coverslip, light underwent total internal reflection as it struck the interface between the glass and the 
solution or cell at a glancing angle. Total internal reflection generates an evanescent field that declines 
exponentially as the distance from the interface increases, depending on the angle at which the light 
strikes the interface [15,16]. The images obtained were projected onto a CCD camera (AxioCam 
MRm, Zeiss) though a dichroic FT500 and band-pass filter (525/50 nm) for EGFP signals, or through a 
dichroic FT470 and band-pass filter (485/20 nm). Up to five cells were imaged on each coverslip. 
3.7. Image Analysis 
To determine the overlap between the different fluorescent molecules, evanescent field images were 
analyzed as described recently [17]. Briefly, the images were low-pass filtered using Metamorph 
(Molecular Devices, Sunnyvale, CA, USA), and a circle 10 pixels in diameter was plotted around each 
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spot analyzed, as well as five further circles outside these spots that were used to calculate the local 
background. We then drew circles 10 pixels in diameter around the NPY-EGFP spots and overlayed 
these circles onto the image of the paired molecules at identical pixel locations. Finally, we determined 
whether the new circle contained a concentric fluorescent point within the 10 pixel circle to quantify 
the co-localization of the fluorophor. Circles were scored as positive if they contained a fluorescent 
spot and negative if they did not. Moreover, the co-localization was only scored as positive when the 
average fluorescence intensity was at least three times the standard deviation of the background. The 
percentage co-distribution was determined in single cells after random co-distribution subtraction, and 
the average values were calculated from the total number of cells analyzed.  
4. Conclusions 
We have developed a new fluorescent beta-adrenergic blocker with an excitation spectrum within 
visible wavelengths. This particular feature allows fluorescence microscopy to be used to observe how 
it accumulates inside secretory vesicles of PC12 cells. This new tool is of particular interest to label 
secretory vesicles, as well as to gain evidence that β-Bs can exert their delaying hypotensive effects 
through the displacement of natural neurotransmitters from sympathetic neurons. 
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